Gefurulimab

Summary

Gefurulimab (CHEMBL5095307) is a phase-3 clinical-stage antibody; indicated across 2 conditions including myasthenia gravis and proteinuria.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 2 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095307
Name	Gefurulimab
Type	Antibody
Max phase	3

Also known as: ALXN-1720, ALXN1720, Gefurulimab, GEFURULIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
myasthenia gravis	3	MONDO:0009688	EFO:0004991
proteinuria	1	MONDO:0003634	HP:0000093

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1	3
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05556096	PHASE3	ACTIVE_NOT_RECRUITING	Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT06607627	PHASE3	RECRUITING	PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
NCT05314231	PHASE1	COMPLETED	Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
NCT06208488	PHASE1	COMPLETED	A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants
NCT06677138	PHASE1	COMPLETED	PK Study of Gefurulimab SC in Healthy Chinese Adult Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).